Quantitative Concept
FDA lifts clinical hold on Atara’s Epstein-Barr T-cell programme
United States Food and Drug Administration, Study on Hold, Atara, Hoist device, Atara ‘s, EBVALLO
Cigna’s Evernorth unveils 2 new programs aimed at GLP-1s
Programs – Publication Format, Glucagon-Like Peptide 1, Cigna ‘s, GLP-1s, Pharmacy facility, Enhance (action), Pharmaceutical Services
Lilly’s Q1 revenue surge overshadowed by CVS dumping Zepbound for Wegovy
Chorionic Villi Sampling, Zepbound, Eli Lilly, Wegovy, Health
BMS to close Illinois site as part of cell therapy manufacturing consolidation
Bristol Myers Squibb, viral vector production, Libertyville Illinois, manufacturing consolidation, Novartis acquisition, cell therapy, cost cuts
Biogen says Leqembi sales are improving slowly following lackluster launch
Leqembi, Biogen, Sales – occupational activity, Growth, Eisai, United States Food and Drug Administration, Improving (qualifier value)
Moderna expands effort to rein in costs in an uncertain environment
Moderna, Financial cost, Uncertainty, Environment
AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails
Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival
Novartis bolsters renal disease pipeline with $1.7B deal for Regulus
Goldcrest, farabursen, Novartis
Immunic’s MS drug shows ‘modest’ brain volume impact, stock tumbles
Multiple Sclerosis, brain volume, Progressive, vidofludimus, calcium, Disability
Regeneron loses bid to fend off DOJ fight over Eylea Medicare payments
False Claims Act, Medicare fraud, average sales price inflation, credit card fees, price concessions, DOJ lawsuit